bluebird bio (BLUE) News Today $4.14 -0.01 (-0.24%) Closing price 04:00 PM EasternExtended Trading$4.16 +0.02 (+0.36%) As of 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 Time Period Bluebird bio reaffirms Carlyle deal as Ayrmid misses deadlineApril 17 at 8:36 AM | finance.yahoo.comBluebird bio shares fall amid acquisition woesApril 16 at 4:56 PM | au.investing.comBluebird reports Ayrmid did not submit binding proposal to acquire the companyApril 16 at 4:56 PM | markets.businessinsider.combluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagementApril 16 at 4:56 PM | finance.yahoo.combluebird bio's board opts for sale to U.S. investment firmsApril 16 at 4:56 PM | bizjournals.combluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.comStockNews.com assumed coverage on shares of bluebird bio in a research report on Sunday. They set a "sell" rating on the stock.April 14 at 1:22 AM | marketbeat.comCharles Schwab Investment Management Inc. Has $231,000 Stock Holdings in bluebird bio, Inc. (NASDAQ:BLUE)Charles Schwab Investment Management Inc. decreased its stake in bluebird bio, Inc. (NASDAQ:BLUE - Free Report) by 95.0% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 27,652 shares of the biApril 3, 2025 | marketbeat.comBluebird Bio Receives $4.50 Per Share Acquisition Proposal From AyrmidApril 3, 2025 | nasdaq.comXcellbio Announces Commercial Licensing & Supply Agreement to Support Commercial Production of Gene Therapy for Sickle Cell diseaseApril 2, 2025 | finance.yahoo.comBluebird Bio price target lowered to $8 from $40 at BarclaysApril 1, 2025 | markets.businessinsider.comBluebird Bio (BLUE) Gets a Buy from BarclaysMarch 31, 2025 | markets.businessinsider.comBluebird Bio Shares Rise After Non-Binding Offer From AyrmidMarch 31, 2025 | marketwatch.comGene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock JumpsMarch 31, 2025 | benzinga.comBluebird Bio confirms receipt non-binding proposal from AyrmidMarch 29, 2025 | markets.businessinsider.comBluebird bio reports another acquisition offer for $45M upfrontMarch 28, 2025 | bizjournals.comBluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- UpdateMarch 28, 2025 | marketwatch.comBluebird bio receives non-binding bid for up to $110.5 millionMarch 28, 2025 | reuters.combluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from AyrmidMarch 28, 2025 | businesswire.comGene therapy loses luster as investors eye quicker returns from weight-loss drugsMarch 21, 2025 | msn.comIn the Thymus We Trust: ProTcell Therapy & the Future of Allogeneic ImmunotherapyMarch 18, 2025 | msn.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 17, 2025 | prnewswire.comMan Cured Of Sickle Cell Disease In New York Thanks To New Gene TherapyMarch 15, 2025 | forbes.comBristol Myers Squibb Buys Out Cancer Cell Therapy Partner 2seventy Bio In $286M DealMarch 12, 2025 | msn.comBristol-Myers Squibb To Acquire 2seventy bio - A Sad But Inevitable End To A Cell Therapy PioneerMarch 12, 2025 | seekingalpha.comBristol Myers acquires cell therapy partner 2seventy bio for about $286 millionMarch 11, 2025 | msn.com2seventy bio, Bluebird’s cell therapy spinout, sells to Bristol Myers for less than $300MMarch 11, 2025 | finance.yahoo.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 11, 2025 | prnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUEMarch 3, 2025 | prnewswire.comBluebird Bio upgraded to Neutral from Underweight at JPMorganFebruary 24, 2025 | markets.businessinsider.comBluebird Bio price target lowered to $5 from $40 at Wells FargoFebruary 24, 2025 | markets.businessinsider.comBluebird bio stock slides for second day on buyout newsFebruary 24, 2025 | msn.comBLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUEFebruary 24, 2025 | businesswire.comOnce a darling of biotech, bluebird sells for less than $30M upfrontFebruary 23, 2025 | bizjournals.comBluebird Bio to Be Acquired by Carlyle Group, SK CapitalFebruary 21, 2025 | msn.comBluebird Bio trading halted, volatility trading pauseFebruary 21, 2025 | markets.businessinsider.comALERT: Rowley Law PLLC is Investigating Proposed Acquisition of bluebird bio, Inc.February 21, 2025 | prnewswire.comOnce high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy makerFebruary 21, 2025 | cnbc.com$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of bluebird bio, Inc. - BLUEFebruary 21, 2025 | prnewswire.comShareholder Alert: Ademi LLP investigates whether bluebird bio, Inc. is obtaining a Fair Price for its Public ShareholdersFebruary 21, 2025 | businesswire.comBLUE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of bluebird bio, Inc. Is Fair to ShareholdersFebruary 21, 2025 | businesswire.combluebird bio Announces Definitive Agreement to be Acquired by Carlyle and SK CapitalFebruary 21, 2025 | businesswire.comHigh-cost sickle cell gene therapies push insurers and Medicaid programs to find new payment modelsFebruary 18, 2025 | cnbc.combluebird bio (NASDAQ:BLUE) Stock Price Passes Below Two Hundred Day Moving Average - Should You Sell?bluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Here's What HappenedFebruary 14, 2025 | marketbeat.combluebird bio, Inc. (NASDAQ:BLUE) Given Consensus Rating of "Hold" by BrokeragesShares of bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) have been assigned an average rating of "Hold" from the nine analysts that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have giFebruary 6, 2025 | marketbeat.comBluebird bio chief business officer Joseph Vittiglio sells $1,759 in stockFebruary 5, 2025 | msn.comBluebird bio's chief commercial officer Klima sells $901 in stockFebruary 5, 2025 | msn.comShort Interest in bluebird bio, Inc. (NASDAQ:BLUE) Drops By 6.6%bluebird bio, Inc. (NASDAQ:BLUE - Get Free Report) was the recipient of a significant drop in short interest during the month of January. As of January 15th, there was short interest totalling 2,410,000 shares, a drop of 6.6% from the December 31st total of 2,580,000 shares. Currently, 25.0% of the shares of the company are sold short. Based on an average daily volume of 405,100 shares, the short-interest ratio is presently 5.9 days.February 3, 2025 | marketbeat.combluebird bio (NASDAQ:BLUE) Share Price Passes Below 200 Day Moving Average - Here's What Happenedbluebird bio (NASDAQ:BLUE) Stock Passes Below 200-Day Moving Average - Time to Sell?February 1, 2025 | marketbeat.comQ4 EPS Estimates for bluebird bio Increased by Analystbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Research analysts at Leerink Partnrs increased their Q4 2024 EPS estimates for shares of bluebird bio in a research note issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now expects that the biotechnology company will post earJanuary 24, 2025 | marketbeat.comCantor Fitzgerald Weighs in on bluebird bio FY2025 Earningsbluebird bio, Inc. (NASDAQ:BLUE - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for bluebird bio in a report released on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt anticipates that the biotechnology company will earn ($23January 23, 2025 | marketbeat.com Remove Ads Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address BLUE Media Mentions By Week BLUE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLUE News Sentiment▼0.430.80▲Average Medical News Sentiment BLUE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLUE Articles This Week▼64▲BLUE Articles Average Week Remove Ads Get bluebird bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Cardiff Oncology News Today Gossamer Bio News Today Design Therapeutics News Today Tevogen Bio News Today TuHURA Biosciences News Today MediWound News Today LifeVantage News Today Eledon Pharmaceuticals News Today Voyager Therapeutics News Today Prime Medicine News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLUE) was last updated on 4/17/2025 by MarketBeat.com Staff From Our Partners[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding bluebird bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share bluebird bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BLUE Stock Free BLUE Stock Alerts